FRANKFURT/LONDON (Reuters) - Bayer has struck an alliance with U.S. biotech firm Dimension Therapeutics to develop a gene therapy for the treatment of haemophilia A, marking renewed interest in an approach to tackle the cause of diseases at a cellular level.




Source: Bayer bets on gene therapy with Dimension deal


David Cottle

UBB Owner & Administrator